9 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEdiabetic macular edemaActive, not recruitingPhase 32026-10-02NCT07449936
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorderRecruitingPhase 2 / Phase 32026-09-30NCT06635148
Extension Study for the Port Delivery System With Ranibizumab (Portal)Neovascular Age-Related Macular DegenerationRecruitingPhase 32026-09-28NCT03683251
Study of ALK-001 on the Progression of Stargardt DiseaseCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Stargardt disease, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorderRecruitingPhase 32026-09-18NCT07419334
An Observational Study of the Progression of Intermediate Age-Related Macular Degenerationage-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorderActive, not recruitingNot stated2026-09-16NCT05300724
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56wet macular degenerationActive, not recruitingPhase 32026-09-03NCT06668064
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)diabetic macular edemaActive, not recruitingPhase 12026-09-02NCT06847854
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degenerationeye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degenerationRecruitingPhase 32026-04-16NCT07064759
A Study to Determine the Safety and Efficacy of NT-501 With MHFMmacular telangiectasia type 2Active, not recruitingPhase 32025-07-10NCT06397131